September 2021 | pyrazoles-derivatives

Our Top Choice Compound:C11H12N2O

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Liu, CF; Liu, M; Dong, L or concate me.. HPLC of Formula: C11H12N2O

HPLC of Formula: C11H12N2O. Liu, CF; Liu, M; Dong, L in [Liu, Chen-Fei; Liu, Man; Dong, Lin] Sichuan Univ, West China Sch Pharm, Educ Minist, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu 610041, Sichuan, Peoples R China published Iridium(III)-Catalyzed Tandem Annulation Synthesis of Pyrazolo[1,2-alpha]cinnolines from Pyrazolones and Sulfoxonium Ylides in 2019, Cited 55. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

A highly efficient iridium-catalyzed cascade annulation of pyrazolones and sulfoxonium ylides to access various pyrazolo[1,2-alpha]cinnoline derivatives has been achieved. This novel approach expanded the application scope of coupling partners to ylides. The control experiments were performed to give insight into the mechanism of this reaction.

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Liu, CF; Liu, M; Dong, L or concate me.. HPLC of Formula: C11H12N2O

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An overview of features, applications of compound:86-92-0

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or concate me.. SDS of cas: 86-92-0

SDS of cas: 86-92-0. In 2021 CHEM-EUR J published article about ENANTIOSELECTIVE ADDITION; TERTIARY ALCOHOLS; PYRAZOLONE DERIVATIVES; ORGANOZINC REAGENTS; ALKYLZINC REAGENTS; ALPHA-KETOESTERS; KETONES; DIETHYLZINC; HYDROXYLATION; DIMETHYLZINC in [Wang, Rong-Hui; Li, Ya-Ling; He, Hong-Jiao; Xiao, You-Cai; Chen, Fen-Er] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China; [Chen, Fen-Er] Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China; [Chen, Fen-Er] Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China in 2021, Cited 67. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0.

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or concate me.. SDS of cas: 86-92-0

The Best Chemistry compound:C5H8N2

Recommanded Product: 3,5-Dimethyl-1H-pyrazole. About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Tuskaev, VA; Zubkevich, SV; Saracheno, D; Gagieva, SC; Dorovatovskii, PV; Kononova, EG; Khrustalev, VN; Zarubin, DN; Bulychev, BM; Kissin, YV or concate me.

An article Nickel(II) complexes with tripodal NNN ligands as homogenous and supported catalysts for ethylene oligomerization WOS:000456751700004 published article about BRANCHED POLYETHYLENE; FUNCTIONALIZED POLYOLEFINS; ALKYLALUMINUM COCATALYST; METAL-COMPLEXES; NITROGEN DONOR; AMINE LIGANDS; POLYMERIZATION; ALUMINUM; NMR; TEMPERATURE in [Tuskaev, Vladislav A.; Zubkevich, Sergei V.; Gagieva, Svetlana Ch.; Bulychev, Boris M.] Moscow MV Lomonosov State Univ, Chem Dept, Leninskie Gory 11, Moscow 119991, Russia; [Tuskaev, Vladislav A.; Kononova, Elena G.; Khrustalev, Victor N.; Zarubin, Dmitry N.] Russian Acad Sci, AN Nesmeyanov Inst Organoelement Cpds, Vavilov Str 28, Moscow 119991, Russia; [Saracheno, Daniele] Dimitri Mendeleev Univ Chem Technol Russia, Higher Coll Chem Russia, Miusskaya Sq 9, Moscow 125047, Russia; [Dorovatovskii, Pavel V.; Khrustalev, Victor N.] Natl Res Ctr, Kurchatov Inst, Moscow, Russia; [Khrustalev, Victor N.] Peoples Friendship Univ Russia RUDN, Moscow, Russia; [Kissin, Yury V.] Rutgers State Univ, Dept Chem & Chem Biol, 123 Bevier Rd, Piscataway, NJ 08854 USA in 2019.0, Cited 73.0. Recommanded Product: 3,5-Dimethyl-1H-pyrazole. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

Four new coordination compounds of nickel (II) with derivatives of N,N-bis(pyrazol-1-ylmethyl)propylamine were synthesized; their composition and structure were confirmed with IR-spectroscopy and elemental analysis. The structures of products 13 and 15 were unambiguously established in an X-ray diffraction study. Compounds 13 and 15 crystallize in the orthorhombic space groups Pna2(1) and P2(1)2(1)2(1) correspondingly and represent a monomeric octahedral nickel complexes, that are typical for tridentate scorpion-type ligands. New method for immobilization of nickel complexes with derivatives of N,N-bis(pyrazol-1-ylmethyl)propylamine on silica gel modified with aminopropyl groups was proposed. The EXAFS/XANES analysis indicated that Ni atom in the supported complexes adopt almost octahedral geometry, being partly surrounded by nitrogen atoms from organic ligand and partly grafted to silica surface through silanol groups, with Br- in outer coordination sphere. Both the original and the supported complexes, when activated with Et2AlCl or Et3Al2Cl3, catalyze ethylene oligomerization with the predominant formation of butene isomers. Generally, the immobilized complexes show higher activity and better selectivity towards 1-butene formation.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Some scientific research about 3,5-Dimethyl-1H-pyrazole

Product Details of 67-51-6. About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Hassanzadeh, C; Rudra, S; Bommireddy, A; Hawkins, WG; Wang-Gillam, A; Fields, RC; Cai, B; Park, J; Green, O; Roach, M; Henke, L; Kim, H or concate me.

Product Details of 67-51-6. Authors Hassanzadeh, C; Rudra, S; Bommireddy, A; Hawkins, WG; Wang-Gillam, A; Fields, RC; Cai, B; Park, J; Green, O; Roach, M; Henke, L; Kim, H in ELSEVIER INC published article about in [Hassanzadeh, Comron; Rudra, Soumon; Cai, Bin; Park, Justin; Green, Olga; Henke, Lauren; Kim, Hyun] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA; [Hassanzadeh, Comron; Rudra, Soumon; Hawkins, William G.; Wang-Gillam, Andrea; Fields, Ryan C.; Cai, Bin; Park, Justin; Green, Olga; Henke, Lauren; Kim, Hyun] Alvin J Siteman Comprehens Canc Ctr, St Louis, MO USA; [Bommireddy, Ani] St Louis Univ, Sch Med, St Louis, MO USA; [Hawkins, William G.; Fields, Ryan C.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Wang-Gillam, Andrea] Washington Univ, Sch Med, Dept Med Oncol, St Louis, MO USA; [Roach, Michael] Canc Ctr Hawaii, Honolulu, HI USA in 2021.0, Cited 25.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

Purpose: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation. Methods and Materials: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5 fractions (biologically effective dose(10) 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription, prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated. Results: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was 16 months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%). Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2), while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%. Conclusions: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted. (C) 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Chemical Properties and Facts of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Peters, GA; Wong, ML; Joseph, JW; Sanchez, LD or concate me.. Formula: C12H12N2O3

Peters, GA; Wong, ML; Joseph, JW; Sanchez, LD in [Peters, Gregory Andrew; Wong, Matthew L.; Joseph, Joshua W.; Sanchez, Leon D.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, 1 Deaconess Rd, Boston, MA 02215 USA; [Peters, Gregory Andrew; Wong, Matthew L.; Joseph, Joshua W.; Sanchez, Leon D.] Harvard Med Sch, Boston, MA 02115 USA published Pulse Rate Variability in Emergency Physicians During Shifts: Pilot Cross-Sectional Study in 2019, Cited 40. Formula: C12H12N2O3. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Background: The high prevalence of physician burnout, particularly in emergency medicine, has garnered national attention in recent years. Objective means of measuring stress while at work can facilitate research into stress reduction interventions, and wearable photoplethysmography (PPG) technology has been proposed as a potential solution. However, the use of low-burden wearable biosensors to study training and clinical practice among emergency physicians (EP) remains untested. Objective: This pilot study aimed to (1) determine the feasibility of recording on-shift photoplethysmographic data from EP, (2) assess the quality of these data, and (3) calculate standard pulse rate variability (PRV) metrics from the acquired dataset and examine patterns in these variables over the course of an academic year. Methods: A total of 21 EP wore PPG biosensors on their wrists during clinical work in the emergency department during a 9-hour shift. Recordings were collected during the first quarter of the academic year, then again during the fourth quarter of the same year for comparison. The overall rate of usable data collection per time was computed. Standard pulse rate (PR) and PRV metrics from these two time points were calculated and entered into Student t tests. Results: More than 400 hours of data were entered into these analyses. Interpretable data were captured during 8.54% of the total recording time overall. In the fourth quarter of the academic year compared with the first quarter, there was no significant difference in median PR (75.8 vs 76.8; P=.57), mean R-R interval (0.81 vs 0.80; P=.32), SD of R-R interval (0.11 vs 0.11; P=.93), root mean square of successive difference of R-R interval (0.81 vs 0.80; P=.96), low-frequency power (3.5×103 vs 3.4×103; P=.79), high-frequency power (8.5×103 vs 8.3×103; P=.91), or low-frequency to high-frequency ratio (0.42 vs 0.41; P=.43), respectively. Power estimates for each of these tests exceeded .90. A secondary analysis of the resident-only subgroup similarly showed no significant differences over time, despite power estimates greater than .80. Conclusions: Although the use of PPG biosensors to record real-time physiological data from EP while providing clinical care seems operationally feasible, this study fails to support the notion that such an approach can efficiently provide reliable estimates of metrics of interest. No significant differences in PR or PRV metrics were found at the end of the year compared with the beginning. Although these methods may offer useful applications to other domains, it may currently have limited utility in the contexts of physician training and wellness.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

New explortion of C12H12N2O3

Formula: C12H12N2O3. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.

An article Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes WOS:000649434300024 published article about DRUG-REACTIONS; MEDICATION USE; OLDER-PEOPLE; CARE; COMORBIDITIES in [Delgado, Joao; Jones, Lindsay; Ballard, Clive; Melzer, David] Univ Exeter, Coll Med & Hlth, Epidemiol & Publ Hlth, Exeter EX1 2LU, Devon, England; [Bradley, Marie C.] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Allan, Louise M.; Clare, Linda] Univ Exeter, Coll Med & Hlth, Ctr Res Ageing & Cognit Hlth, Exeter EX1 2LU, Devon, England; [Fortinsky, Richard H.] Univ Connecticut, Sch Med, Ctr Aging, Mansfield, CT 06030 USA; [Hughes, Carmel M.] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland in 2021, Cited 30. Formula: C12H12N2O3. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3

Importance: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. Objective: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). Design: retrospective cohort. Setting: primary care electronic health records linked to hospital discharge data from England. Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. Methods: Screening Tool of Older Persons’ Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. Results: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.021.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P< 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.022.57; P < 0.04). Conclusion: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities. Formula: C12H12N2O3. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.

Our Top Choice Compound:83-10-3

About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.. Recommanded Product: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Recommanded Product: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. In 2021 AGE AGEING published article about DRUG-REACTIONS; MEDICATION USE; OLDER-PEOPLE; CARE; COMORBIDITIES in [Delgado, Joao; Jones, Lindsay; Ballard, Clive; Melzer, David] Univ Exeter, Coll Med & Hlth, Epidemiol & Publ Hlth, Exeter EX1 2LU, Devon, England; [Bradley, Marie C.] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Allan, Louise M.; Clare, Linda] Univ Exeter, Coll Med & Hlth, Ctr Res Ageing & Cognit Hlth, Exeter EX1 2LU, Devon, England; [Fortinsky, Richard H.] Univ Connecticut, Sch Med, Ctr Aging, Mansfield, CT 06030 USA; [Hughes, Carmel M.] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland in 2021, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Importance: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. Objective: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). Design: retrospective cohort. Setting: primary care electronic health records linked to hospital discharge data from England. Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. Methods: Screening Tool of Older Persons’ Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. Results: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.021.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P< 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.022.57; P < 0.04). Conclusion: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.. Recommanded Product: 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Never Underestimate The Influence Of 3-Methyl-1-p-tolyl-5-pyrazolone

SDS of cas: 86-92-0. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or concate me.

An article Catalytic Asymmetric Addition of Diorganozinc Reagents to Pyrazole-4,5-Diones and Indoline-2,3-Diones WOS:000615937000001 published article about ENANTIOSELECTIVE ADDITION; TERTIARY ALCOHOLS; PYRAZOLONE DERIVATIVES; ORGANOZINC REAGENTS; ALKYLZINC REAGENTS; ALPHA-KETOESTERS; KETONES; DIETHYLZINC; HYDROXYLATION; DIMETHYLZINC in [Wang, Rong-Hui; Li, Ya-Ling; He, Hong-Jiao; Xiao, You-Cai; Chen, Fen-Er] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China; [Chen, Fen-Er] Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China; [Chen, Fen-Er] Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China in 2021, Cited 67. SDS of cas: 86-92-0. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0

SDS of cas: 86-92-0. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or concate me.

Chemical Properties and Facts of C5H8N2

About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Massoud, SS; Perez, ZE; Courson, JR; Fischer, RC; Mautner, FA; Vanco, J; Cajan, M; Travnicek, Z or concate me.. Category: pyrazoles-derivatives

An article Slow magnetic relaxation in penta-coordinate cobalt(II) field-induced single-ion magnets (SIMs) with easy-axis magnetic anisotropy WOS:000563083800029 published article about STATE PERTURBATION-THEORY; MOLECULE MAGNET; ZERO-FIELD; DONOR LIGANDS; NI-II; COMPLEXES; VALENCE; COPPER(II); EFFICIENT; BEHAVIOR in [Massoud, Salah S.; Perez, Zoe E.; Courson, Jessica R.] Univ Louisiana Lafayette, Dept Chem, POB 94370, Lafayette, LA 70504 USA; [Massoud, Salah S.] Alexandria Univ, Fac Sci, Dept Chem, Alexandria, Egypt; [Fischer, Roland C.] Graz Univ Technol, Inst Anorgan Chem, A-8010 Graz, Austria; [Mautner, Franz A.] Graz Univ Technol, Inst Phys & Theoret Chem, A-8010 Graz, Austria; [Vanco, Jan; Cajan, Michal; Travnicek, Zdenek] Palacky Univ Olomouc, Reg Ctr Adv Technol & Mat, Div Biol Act Complexes & Mol Magnets, Slechtitelu 27, CZ-78371 Olomouc, Czech Republic in 2020.0, Cited 99.0. Category: pyrazoles-derivatives. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

Two penta-coordinate complexes of the general formula [Co(L-n)(NCS)]ClO4, where L-1= {bis[(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]-[(3,4-dimethoxypyridin-2-yl)methyl]}amine and L-2= {bis[(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]}amine, have been synthesized and thoroughly characterized. Each of the cobalt(ii) atoms is penta-coordinated in the {CoN5} donor set with a distorted square-pyramidal geometry in [Co(L-1)(NCS)]ClO4 center dot MeOH (1), while the vicinity of the central atom can be described as a distorted trigonal-bipyramidal geometry in [Co(L-2)(NCS)]ClO4(2) as revealed using the SHAPE analysis. Differences in interatomic parameters among the cobalt(ii) and donor atoms in 1 and 2 have definite impact on the magnetic features of both compounds. The complexes show an easy-axis magnetic anisotropy (D = -38.5 cm(-1) for 1 and D= -8.5 for 2), and both complexes reveal a large rhombicity with E/D = 0.21 for 1 and E/D = 0.29 for 2. The ZFS parameters (g, D and E) were also calculated using CASSCF/NEVPT2 methods and they are in good agreement with those determined from experimental data. A frequency dependent out-of-phase susceptibility has been observed in external magnetic field (B-dc= 0.1 T) revealing the following parameters of slow relaxation of magnetization for 1: energy of the spin reversal barrier, U-eff = 16.0 cm(-1)(U-eff/kB = 23.0 K) and the relaxation time, tau(0)= 1.28 x 10(-6)s. In the case of complex 2, no maxima of frequency dependent out-of-phase susceptibility have been observed and thus, the value of U-eff= 17 cm(-1) has been estimated using the expression U-eff = vertical bar D vertical bar x (S-2- 1/4). It has been demonstrated that the degree of substitution and the type of substituents on the pyridyl moieties of the tripodal ligands (L-1 and L-2) used in these penta-coordinate cobalt(ii) complexes have significant impact on structural and magnetic features.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Search for chemical structures by a sketch :83-10-3

About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or concate me.. Formula: C12H12N2O3

I found the field of Oncology very interesting. Saw the article Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients published in 2020. Formula: C12H12N2O3, Reprint Addresses Buchler, T (corresponding author), Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic.; Buchler, T (corresponding author), Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic.. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.